Navigation Links
Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Date:1/14/2008

he world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

References

1. Aul C, Giagounidis A, Germing U. Epidemiological features of

myelodysplastic syndromes: results from regional cancer surveys and

hospital-based statistics. Int J. Hematol. 2001;73(4):405-10.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. In particular, we can not assure you that our MAA for Vidaza will be acceptable to the EMEA or that Vidaza will ultimately receive a marketing authorization in the EU. Important factors that could cause or contribute to such differences include the regulatory status and timing of regulatory approvals for Vidaza; the impact of competition from other products sold by Pharmion's competitors in the EU; the regulatory environment and changes in the health policies and structure of various countries; acceptance and demand for new pharmaceutical products and new therapies, uncertainties regarding Pharmion's ability to enforce market exclusivities in member states of the EU; failure of third-party manufacturers to produce the product volumes required on a timely basis, fluctuations in currency exchange rates, and other factors that are discussed in Pharmion's filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made,
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
2. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
3. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
4. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
5. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
8. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 /PRNewswire-iReach/ -- "Spain Aesthetic Lasers and Energy ... data on the Spain Aesthetic Lasers and Energy ... of US dollars, volume (in units) and average ... Body Contouring Devices (Laser-Assisted Liposuction (LAL) Devices (Nd:YAG ... Ultrasound-Assisted Liposuction (UAL) Devices and Power Assisted Liposuction ...
(Date:9/15/2014)... /PRNewswire-iReach/ -- On September 8, 2014, Dr. ... a Citizen Petition to Dr. Margaret Hamburg ... another Black Box Warning to Levaquin, Cipro, and ... a Black Box Warning for the following psychiatric ... or acts, loss of consciousness, delirium, depressed level ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 ... Brussels:UCB) today announced results from several exploratory analyses of ... with low bone mineral density (BMD). Romosozumab is an ... inhibiting the protein sclerostin, thereby increasing bone formation and ... American Society for Bone and Mineral Research (ASBMR) 2014 ...
Breaking Medicine Technology:Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 2Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 3Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 4Spain Aesthetic Lasers and Energy Devices Market (LAL, RFAL, PAL, HIFU) Outlook to 2020 5Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 2Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15
(Date:9/16/2014)... Triad Semiconductor, Inc. today announced that David ... former President of Linear Technology Corporation was appointed to ... technology and business expertise, and we are delighted that ... Hayden, Triad CEO and chairman. , Mr. Bell brings ... semiconductor experience to Triad's board. From 2008 to 2012, ...
(Date:9/16/2014)... The Fertility Centers of New England is ... The collaboration will give patients access to high-quality frozen ... the Fertility Centers of New England. , Fairfax Egg ... largest selection of frozen donor eggs. Access to frozen ... , The Donor is already screened and her ...
(Date:9/16/2014)... BamboofloorChina.com, a famous online supplier of bamboo products, has ... bamboo panels . The firm is now offering big ... high quality items. Please note that the big sale ... , According to the company’s chief executive officer, ... visit BamboofloorChina.com before September 28. BamboofloorChina.com is offering more ...
(Date:9/15/2014)... September 16, 2014 With the variety ... is difficult to know the details on each one. ... the potential substances falling into their teen’s hands. ... marijuana itself among high school students. With varied, misleading ... and elsewhere, it can be difficult for parents to ...
(Date:9/15/2014)... Hastings and Hastings, an experienced and established ... flat attorney fee for personal injury cases. The firm ... portion possible of their settlement or recovery as a ... personal property. In addition, Hastings and Hastings makes an ... that no fees are due unless a settlement or ...
Breaking Medicine News(10 mins):Health News:David Bell Joins Triad Semiconductor's Board of Directors 2Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Cheap Bamboo Panels Unveiled By Famous Online Supplier BamboofloorChina.com 2Health News:Teen Rehab Center CEO Releases Top 4 Facts Parents Must Know About Synthetic Marijuana 2Health News:Teen Rehab Center CEO Releases Top 4 Facts Parents Must Know About Synthetic Marijuana 3Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3
... is a potentially debilitating childhood disease. Early detection ... term joint damage and disability. Research has shown ... assessments in joint activity and sub-clinical disease, according ... Roentgen Ray Society,s annual meeting. The study, performed ...
... HealthDay Reporter , WEDNESDAY, May 4 (HealthDay News) -- ... prescribed inhaled steroids, British researchers found that the oral ... The oral medications, known as leukotriene-receptor antagonists, "have shown ... be considered for any patient, not as a last ...
... May 4 (HealthDay News) -- A gene essential to cardiac ... defects that cause a major proportion of childhood death from ... defects -- all malformations of the left ventricular outflow tract ... may play a role. "It is estimated that there ...
... LOUIS and DES MOINES, Iowa, May 4, 2011 The ... $4 million grant from the Howard G. Buffett Foundation to ... The grant will help fund the completion of the development ... Africans who depend upon sorghum as their staple diet. ...
... for cancer during childhood have an increased risk ... according to a new study in Gastroenterology ... Association (AGA) Institute. Compared with their siblings, cancer ... of the upper GI tract, lower GI tract ...
... 4 (HealthDay News) -- Vigorous exercise offers more of ... study finds. U.K. researchers compared 11 sedentary people ... assessed before, during, immediately following, and 20 minutes after ... more negative during and immediately after high-intensity exercise, compared ...
Cached Medicine News:Health News:Sonography complements physical exam in identifying juvenile inflammatory arthritis in children 2Health News:Asthma Pills Work as Well as Inhaled Steroids: Study 2Health News:Asthma Pills Work as Well as Inhaled Steroids: Study 3Health News:New Gene Linked to Congenital Heart Defects 2Health News:Grant funds next phase in bringing healthier sorghum closer to underserved communities 2Health News:Childhood cancer survivors are at increased risk for ongoing post-therapy GI complications 2
... Laboratories Platelia Aspergillus EIA is a one-stage ... monoclonal antibody EBA-2 to detect circulating galactomannan ... 3 hours. , ,When used in conjunction ... is an aid in the diagnosis of ...
... The GreenLight PV Laser System ... the Prostate) Procedure for the ... (BPH) allows the urologist to ... a TURP with the safety ...
... diagnosis is generally confirmed by a positive heterophil ... however, is not indicated by the heterophil antibody ... - 20 percent of children. Detection and ... fully ascertain the stage of EBV infection. ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
Medicine Products: